Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
103.86
+7.27 (7.53%)
At close: Nov 6, 2026, 4:00 PM EST
103.00
-0.86 (-0.83%)
After-hours: Nov 6, 2026, 7:30 PM EST
Spyre Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
130
Market Cap
9.86B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 886.00K | -1.44M | -61.96% |
| Dec 31, 2022 | 2.33M | -16.41M | -87.57% |
| Dec 31, 2021 | 18.74M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Madrigal Pharmaceuticals | 1.43B |
| Caris Life Sciences | 989.61M |
| Corcept Therapeutics | 963.65M |
| TG Therapeutics | 799.54M |
| Arrowhead Pharmaceuticals | 669.50M |
| Krystal Biotech | 470.03M |
| Twist Bioscience | 431.80M |
| Protagonist Therapeutics | 281.99M |
SYRE News
- 16 hours ago - Spyre Therapeutics Announces Grants of Inducement Awards - GlobeNewsWire
- 3 days ago - Spyre Therapeutics price target lowered to $120 from $123 at Wedbush - TheFly
- 3 days ago - Spyre Therapeutics price target raised to $131 from $123 at Stifel - TheFly
- 3 days ago - Spyre Therapeutics reports Q3 EPS (94c), consensus (84c) - TheFly
- 3 days ago - Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 days ago - Spyre Therapeutics Quarterly report: Q3 2026 - Filings
- 4 days ago - Spyre Therapeutics Earnings release: Q3 2026 - Filings
- 18 days ago - Citi ups Spyre target, opens ‘upside 90-day catalyst watch’ - TheFly